CES2 and tuberculosis: We investigated the between-patient variability of rifampicin pharmacokinetics parameters (Cmax and AUC0–7 h) in Ethiopian adults commencing TB treatment and the role of pharmacogenetic variations in drug transporter proteins (SLCO1B1 and ABCB1) and metabolising enzymes relevant for rifampicin disposition (AADAC2 and CES2).